|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Regenxbio Inc (RGNX)
DETREND PRICE OSCILLARTOR
Trading: BUY @ $41.86
Signal Strength: STRONG
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.
Regenxbio Inc (NASDAQ:RGNX) currently has a confirmed uptrend. Price is currently above the displaced moving average for RGNX Currently, the return on DPO20 is -0.2%.
The Detrended Price Oscillator (DPO) is an indicator designed to remove trend from price and make it easier to identify cycles. DPO does not extend to the last date because it is based on a displaced moving average. However alignment with the most recent is not an issue because DPO is not a momentum oscillator. Instead DPO is used to identify cycle’s highs/lows and estimate cycle length.
Calculation: Detrended Price Oscillator (DPO):
1) Price (X/2 + 1) periods ago minus X-period simple moving average.
Where X is the number of periods;
PROFILE: Regenxbio Inc (RGNX)
Stock Exchange: NASDAQ
Company: Regenxbio Inc
Ticker Codes: | RGNX | NASDAQ:RGNX |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501 for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111 to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121 for the treatment of neurological symptoms of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV technology platform to other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
|NVAX Novavax Inc||4.85||23.1||3,687,640||-2.5||BEARISH|
|ICON Iconix Brand||1.19||14.4||348,800||-0.76||BEARISH|
|BCRX BioCryst Pharmaceuticals||2.85||10.3||2,873,485||-5.9||BEARISH|
|STKL Sunopta Inc||2.9||7.4||191,000||-0.72||BEARISH|
|WVE WAVE Life Sciences||33.15||5.9||191,800||-0.89||BEARISH|
|ADMS Adamas Pharma||5.95||5.9||365,600||-1.21||BEARISH|
|SYRS Syros Pharmaceuticals||5.1||5.8||218,894||-0.2||BEARISH|
|TGTX Tg Therapeuticscmn||8.19||4.9||1,985,828||-0.14||BEARISH|
|AMPH Amphastar Pharma||19.51||4.7||361,600||-0.51||BEARISH|
|CNCE Concert Pharmaceutic||7.54||4.4||38,600||-1.56||BEARISH|